Carefully assess the patient’s overall health, including cardiovascular function and risk of stroke, before starting Abilify. Patients with a history of seizures should be monitored closely.
Prioritize non-pharmacological interventions, like behavioral therapies and environmental modifications, whenever possible. Abilify should be considered only when these measures prove insufficient.
Start with the lowest effective dose (typically 1-2 mg/day) and titrate slowly to minimize side effects. Regularly monitor for tardive dyskinesia, extrapyramidal symptoms, and hyperglycemia. Document these observations meticulously.
Regular blood glucose monitoring is recommended, particularly in patients with diabetes or risk factors for diabetes. Weight monitoring is also advisable, as weight gain is a potential side effect.
Closely monitor the patient’s mental status for any worsening of psychosis or the emergence of new symptoms. Regular cognitive assessments may be beneficial to track cognitive function.
Family involvement is key. Educate caregivers about potential side effects and the importance of reporting any concerns promptly. Regular communication between the healthcare provider and the patient’s caregivers is crucial for optimal management.
Regularly reassess the need for continued Abilify treatment. Consider tapering and discontinuing the medication if symptoms improve or if side effects outweigh the benefits. Abrupt cessation should be avoided.
Document all decisions regarding Abilify prescribing, including dosage adjustments, side effect monitoring, and the rationale behind these decisions, in the patient’s medical record.
